COVID-19 susceptibility and severity for dyslipidemia: A mendelian randomization investigation
Background: The severe acute respiratory syndrome coronavirus in 2019 (COVID-19) is still spreading and causing deaths worldwide, which further increased the burden of chronic diseases. Dyslipidemia is a common metabolic syndrome, which is a major risk factor for cardiovascular disease. However, stu...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-09-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023074558 |
| _version_ | 1797669725633773568 |
|---|---|
| author | Yi Liang Liang Liu Bo Liang |
| author_facet | Yi Liang Liang Liu Bo Liang |
| author_sort | Yi Liang |
| collection | DOAJ |
| description | Background: The severe acute respiratory syndrome coronavirus in 2019 (COVID-19) is still spreading and causing deaths worldwide, which further increased the burden of chronic diseases. Dyslipidemia is a common metabolic syndrome, which is a major risk factor for cardiovascular disease. However, studies on whether there is a direct causal relationship between COVID-19 and the exacerbation of hyperlipidemia are still scarce. Methods: Two-sample Mendelian randomization was conducted using publicly available summary statistics from independent cohorts of European ancestry. For COVID-19 and hyperlipidemia, we used data from the ieu open GWAS project database. Inverse variance-weighted, mendelian randomization Egger, weighted median, simple mode, and weighted mode mendelian randomization analyses were performed, together with a range of sensitivity analyses. Results: There is no direct causal relationship between COVID-19 and dyslipidemia, regardless of COVID-19 severity or either dyslipidemic outcome. In combination with previous studies, the reason for the clinical outcome that COVID-19 increased the burden of dyslipidemia may be due to the exacerbation of pre-existing disease caused by COVID-19. Conclusions: COVID-19 has no direct causal relationship with dyslipidemia. |
| first_indexed | 2024-03-11T20:48:42Z |
| format | Article |
| id | doaj.art-b501de86bf454e3da4e24447efdb7039 |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-03-11T20:48:42Z |
| publishDate | 2023-09-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-b501de86bf454e3da4e24447efdb70392023-10-01T06:02:58ZengElsevierHeliyon2405-84402023-09-0199e20247COVID-19 susceptibility and severity for dyslipidemia: A mendelian randomization investigationYi Liang0Liang Liu1Bo Liang2Geriatric Medicine Department, The Second Hospital of Traditional Chinese Medicine in Sichuan Province, Chengdu, ChinaDepartment of Nephrology, The Key Laboratory for the Prevention and Treatment of Chronic Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Nephrology, The Key Laboratory for the Prevention and Treatment of Chronic Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, China; Corresponding author.Background: The severe acute respiratory syndrome coronavirus in 2019 (COVID-19) is still spreading and causing deaths worldwide, which further increased the burden of chronic diseases. Dyslipidemia is a common metabolic syndrome, which is a major risk factor for cardiovascular disease. However, studies on whether there is a direct causal relationship between COVID-19 and the exacerbation of hyperlipidemia are still scarce. Methods: Two-sample Mendelian randomization was conducted using publicly available summary statistics from independent cohorts of European ancestry. For COVID-19 and hyperlipidemia, we used data from the ieu open GWAS project database. Inverse variance-weighted, mendelian randomization Egger, weighted median, simple mode, and weighted mode mendelian randomization analyses were performed, together with a range of sensitivity analyses. Results: There is no direct causal relationship between COVID-19 and dyslipidemia, regardless of COVID-19 severity or either dyslipidemic outcome. In combination with previous studies, the reason for the clinical outcome that COVID-19 increased the burden of dyslipidemia may be due to the exacerbation of pre-existing disease caused by COVID-19. Conclusions: COVID-19 has no direct causal relationship with dyslipidemia.http://www.sciencedirect.com/science/article/pii/S2405844023074558COVID-19DyslipidemiaMendelian randomization |
| spellingShingle | Yi Liang Liang Liu Bo Liang COVID-19 susceptibility and severity for dyslipidemia: A mendelian randomization investigation Heliyon COVID-19 Dyslipidemia Mendelian randomization |
| title | COVID-19 susceptibility and severity for dyslipidemia: A mendelian randomization investigation |
| title_full | COVID-19 susceptibility and severity for dyslipidemia: A mendelian randomization investigation |
| title_fullStr | COVID-19 susceptibility and severity for dyslipidemia: A mendelian randomization investigation |
| title_full_unstemmed | COVID-19 susceptibility and severity for dyslipidemia: A mendelian randomization investigation |
| title_short | COVID-19 susceptibility and severity for dyslipidemia: A mendelian randomization investigation |
| title_sort | covid 19 susceptibility and severity for dyslipidemia a mendelian randomization investigation |
| topic | COVID-19 Dyslipidemia Mendelian randomization |
| url | http://www.sciencedirect.com/science/article/pii/S2405844023074558 |
| work_keys_str_mv | AT yiliang covid19susceptibilityandseverityfordyslipidemiaamendelianrandomizationinvestigation AT liangliu covid19susceptibilityandseverityfordyslipidemiaamendelianrandomizationinvestigation AT boliang covid19susceptibilityandseverityfordyslipidemiaamendelianrandomizationinvestigation |